![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Finds Keytruda Not Cost-Effective in Bladder Cancer
NICE Finds Keytruda Not Cost-Effective in Bladder Cancer
![](https://www.fdanews.com/ext/resources/test/Device_Images3/moneyinhand.gif?t=1435858774&width=430)
August 9, 2017
The UK National Institute for Health and Care Excellence ruled that Merck’s cancer immunotherapy Keytruda is not cost-effective in metastatic urothelial carcinoma.
The agency said it had trouble finding an appropriate model to assess the drug’s cost-effectiveness, but said “all plausible estimates” put the cost-effectiveness higher than it considers acceptable for end-of-life treatments.
NICE said the pre-discount price of £2,630 ($3,425) per 100 mg vial is too high even though the drug is likely to extend patient lives by more than three months.
Upcoming Events
-
21Oct